NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Incyte Corporation
Intensity Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Duke University
Northwestern University